Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191239 | 0.90 | MEN1 (0.48) | SYKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3205700 | 0.84 | CTSS (0.47) | SYKMEN1KMT2AP2RX7GPR119 | |
| SCHEMBL25231274 | 0.84 | SYK (0.47) | SYKMEN1KMT2ALMNAP2RX7 | |
| SCHEMBL26986846 | 0.83 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL15054425 | 0.83 | MEN1 (0.45) | SYKMEN1KMT2AP2RX7GPR119 | |
| SCHEMBL22776170 | 0.83 | SYK (0.47) | SYKMEN1KMT2ALMNAP2RX7 | |
| SCHEMBL22041846 | 0.81 | SYK (0.43) | SYKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4297687 | 0.81 | MEN1 (0.47) | SYKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1446859 | 0.81 | MEN1 (0.48) | SYKMEN1KMT2AP2RX7GPR119 | |
| SCHEMBL22233161 | 0.80 | L3MBTL1 (0.43) | SYKMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | SYK 2438/4885MEN1 4216/4885KMT2A 4067/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | SYK 2438/4885MEN1 4216/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.